Plasmodium falciparum intra-parasitic heme (FP-IX)

Plasmodium falciparum intra-parasitic heme, specifically ferriprotoporphyrin IX (FP-IX), is a toxic byproduct generated during the intraerythrocytic stage of the malaria parasite's life cycle (PubMed: 15522121). As the parasite digests host hemoglobin to obtain amino acids, it releases large quantities of free heme, which can cause oxidative damage to parasitic membranes and proteins (Nature: 10.1038/355448a0). To survive, the parasite detoxifies this heme by sequestering it into an insoluble crystalline pigment called hemozoin, or malaria pigment (NCBI: NBK2246). This biocrystallization process is a critical vulnerability and serves as the primary target for several classes of antimalarial drugs. Quinoline-based drugs, such as chloroquine and quinine, bind to heme and prevent its incorporation into hemozoin, leading to the accumulation of toxic free heme that kills the parasite (PubMed: 11375454). Additionally, artemisinin-based compounds are activated by the iron (Fe) center of heme, generating free radicals that damage parasitic components (PubMed: 16126312). Consequently, intra-parasitic heme represents one of the most successful and clinically validated targets in the history of antimalarial chemotherapy. However, the emergence of resistance, often mediated by mutations in transporters like PfCRT, remains a significant therapeutic challenge (PubMed: 11140678).

Other names

Ferriprotoporphyrin IXFP-IXHematinParasitic hemeHemozoin precursorMalaria pigment precursor

Inhibition of heme biocrystallization into hemozoin and heme-mediated activation of endoperoxide drugs to generate toxic free radicals.